ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing Costs
June 15, 2022 08:00 ET
|
ProKidney
WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”),...
Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update
June 07, 2022 08:00 ET
|
ProKidney
Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 WINSTON-SALEM, N.C., June 07, 2022 (GLOBE...
ProKidney to present at upcoming investor conferences
May 20, 2022 09:00 ET
|
ProKidney
WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...
ProKidney highlights key registrational program elements supporting advancement of REACT®
May 03, 2022 08:00 ET
|
ProKidney
WINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...
ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer
April 28, 2022 08:00 ET
|
ProKidney
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022
April 18, 2022 09:30 ET
|
ProKidney
WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT)...
ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®
April 12, 2022 08:00 ET
|
ProKidney
WINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”),...
ProKidney Appoints Todd C. Girolamo as General Counsel
March 28, 2022 08:00 ET
|
ProKidney
WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and...
ProKidney to Present REACT® at 4th Annual CKD Summit
March 01, 2022 08:05 ET
|
ProKidney
Presentation to include data on Mechanism of Action, clinical trials to-date and current regulatory status WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a...
ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease
January 27, 2022 08:00 ET
|
ProKidney
Article published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading...